jungle wild casino game

French connection on cards for Uttar Pradesh schools via language lessons

Offering patients an injection is more effective than the current care of steroid tablets and cuts the need for further treatment by 30%, according to a study. Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used as a repeat treatment for severe asthma at a low dose, but a new clinical trial has found that a higher single dose can be very effective if injected at the time of a flare-up. The findings, published in the Lancet Respiratory Medicine, included 158 people who needed medical attention in A&E for their asthma or COPD attack (COPD is a group of lung conditions that cause breathing difficulties). Patients were given a quick blood test to see what type of attack they were having, with those suffering an “eosinophilic exacerbation” involving eosinophils (a type of white blood cell) being suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according to the scientists. The clinical trial, led by King’s College London and carried out at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, saw patients randomly split into three groups. One group received the benralizumab injection and dummy tablets, another received standard care (prednisolone steroids 30mg daily for five days) and a dummy injection, and the third group received both the benralizumab injection and steroids. After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better in people on benralizumab. And after 90 days, there were four times fewer people in the benralizumab group who failed treatment compared with those receiving steroids. Treatment with the benralizumab injection also took longer to fail, meaning fewer visits to a GP or hospital for patients, researchers said. Furthermore, people also reported a better quality of life on the new regime. Scientists at King’s said steroids can have severe side-effects such as increasing the risk of diabetes and osteoporosis, meaning switching to benralizumab could provide huge benefits. Lead investigator Professor Mona Bafadhel, from King’s, said: “This could be a game-changer for people with asthma and COPD. “Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined. “Benralizumab is a safe and effective drug already used to manage severe asthma. “We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.” Researchers said benralizumab could also potentially be administered safely at home or in a GP practice, as well as in A&E. First author Dr Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia, said: “Our study shows massive promise for asthma and COPD treatment. “COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. “We need to provide these patients with life-saving options before their time runs out.” Dr Samantha Walker, director of research and innovation at Asthma and Lung UK, welcomed the findings but said: “It’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is.” AstraZeneca provided the drug for the study and funded the research, but had no input into trial design, delivery, analysis or interpretation.

Washington did swing right in the 2024 presidential election after allJudge Arun Subramanian ruled to deny bail for Sean "Diddy" Combs on Friday. Both federal prosecutors and Combs' attorneys submitted their final letters about whether the music mogul should be allowed out on bail on Monday. Prosecutors argued that Combs’ attempt to influence witnesses while in jail “constitutes obstruction” of his criminal case. They also called out Combs’ “recent efforts to influence the jury pool” through a social media campaign organized by his children. Defense attorneys said that their client's conduct was protected free speech, meant to combat “outrageous claims about Mr. Combs” by “government agents, plaintiffs’ attorneys, and others with questionable motives.” Subramanian had asked the parties to submit these final arguments in writing and said he would issue a written decision on bail. Combs, who pleaded not guilty to racketeering conspiracy, sex trafficking and prostitution charges, has offered to remain on home confinement in a three-bedroom apartment on Manhattan’s Upper East Side with 24/7 security guards and restrictions on visitors and communications. Last Friday, the defense called the proposed conditions “far more restrictive” than Combs faces in jail. They included limiting phone calls to lawyers, restricting visitors other than lawyers and specific family members, keeping a visitation log, and avoiding contact with witnesses or potential witnesses. However, federal prosecutors have said there are no conditions that can reduce Combs’ risk of tampering with witnesses or shaping the opinions of potential jurors. They also brought up a 2016 video of Combs attacking then-girlfriend and protégé Cassie Ventura in a hotel hallway, saying that it showed the danger he could pose to women if allowed out on bail. In court last Friday, prosecutors summarily said that Combs "cannot be trusted" to follow the rules of a pretrial release. Copyright © 2024, ABC Audio. All rights reserved.

Coach Prime, CU Buffs focused on ending regular season on high noteUntil now, Ms Weinstein has been the US firm’s vice president and managing director in the UK and Ireland, having previously worked at Unilever. She said her focus will be on “unlocking AI-powered growth for everyone”, calling the current AI boom a “pivotal” time for the tech giant. Google has joined many of its rivals in launching a string of high-profile generative AI products in recent times, led by the firm’s generative AI-powered assistant, Gemini. “Europe, the Middle East and Africa is an amazingly diverse and varied region, but the enormous growth opportunity that AI can create is universal,” she said. “My focus will be on unlocking that AI-powered growth for everyone – users, businesses, partners and governments across every part of the region. “I’m excited to be stepping into this role at a pivotal time, in a company where I’ve spent the last ten years and leading a region where I’ve spent much of my life.” Google employs more than 29,000 people across Europe, the Middle East and Africa, with 56 offices across 35 countries in those regions working on many of the firm’s largest products, including its search engine, the Android mobile operating system and its Chrome web browser. Its AI research arm, at Google DeepMind, is also led from London. Philipp Schindler, Google senior vice president and chief business officer, said: “This is the AI era and we are only just beginning to see its transformative impact on business and society. “In such a pivotal moment for technology, I’m thrilled we’ve appointed a visionary leader to be our President of Google EMEA. “Debbie brings a track record of unlocking growth that benefits everyone, alongside the passion and focus needed to help our customers succeed, as we bring the best of Google’s Gemini-era to everyone across EMEA.”

Earl Holliman Dies: ‘Police Woman’ & ‘Forbidden Planet’ Actor With Dozens Of Film & TV Credits Was 96